Humana Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: November-2026Ownership Structure
Ownership Analysis
Humana has no majority shareholder, despite concentrated positions among several large asset managers. Dodge & Cox's approximately 9.11% holding and BlackRock's 8.68% give each a meaningful voice in governance. They do not displace the board's responsibility for a company with $129.664 billion of 2025 revenue and regulated insurance subsidiaries.The October 2026 clinic agreement adds a separate ownership relationship. BlackRock-managed capital was set to hold a majority of the new clinic venture, with CenterWell remaining a minority investor and operator. Those clinic economics are separate from ownership of Humana itself. The board must assess both the insurance recovery and the cost of financing care delivery. Stronger parent-level flexibility is useful only if the underlying arrangements preserve acceptable returns and adequate control over patient service quality.Insurance regulation creates another limit on the assumption that all group resources can be directed freely from the parent. A profitable subsidiary may still need capital to support covered risks and future claims. The board therefore manages both economic returns and the ability to meet policyholder obligations. Sustainable underwriting and access to capital carry more weight than the size of reported premium revenue. The central ownership responsibility is to maintain a viable insurer while deciding which care-delivery investments improve the long-term economics of that insurance exposure.The clinic arrangements make those decisions more layered. Outside financing can accelerate development and change balance-sheet obligations, but it also allocates part of the future economic benefit to another investor. CenterWell's management role preserves operating involvement without necessarily giving Humana the entire return on each clinic asset. The attractive outcome is an arrangement that funds appropriate expansion at a cost consistent with mature operating returns. It would be weaker if financing flexibility merely delayed recognition of poor clinic economics. Parent shareholders need the board to evaluate the partnership as a capital allocation decision, not simply as evidence of expansion.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Dodge & Cox, BlackRock and the two separately reporting Vanguard managers together hold approximately 29.17% in the June 2026 positions. State Street adds another 4.54%. The two Vanguard entities are separately reported managers, so an older consolidated Vanguard Group percentage should not be layered onto these positions.For shareholders, the immediate financial issue is insurance profitability. Humana's third-quarter 2026 benefit ratio of 93.7% left limited premium margin before administration and other costs, even as revenue grew. The raised adjusted earnings outlook of at least $9.50 per share reflects improved expectations while cost pressure persists. Institutional owners must weigh enrollment growth against pricing adequacy, quality ratings and claims development. Shareholder concentration cannot substitute for disciplined underwriting or resolve uncertainty about future medical utilization.The difference between an investment manager's public shareholding and its private financing role can also complicate the apparent concentration of influence. BlackRock-managed portfolios hold HUM shares, while other managed capital participates in specific clinic arrangements. Those claims should not be combined into a single percentage of Humana ownership. The terms of each relationship determine whether the parent company's interests are adequately protected. A financing partner's return from clinic assets can differ materially from the return available to ordinary investors in the insurance and services group.For the wider register, the most demanding question is whether membership growth is producing an economically sound book of business. Higher enrollment increases the potential revenue base, but the associated claims experience determines whether that scale creates value. The benefit ratio provides an immediate measure of pressure, while reserving and future pricing influence subsequent periods. Diversified owners cannot resolve those operating issues by agreeing on a preferred valuation. Their contribution lies in holding directors accountable for underwriting discipline, capital adequacy and a credible connection between investment in CenterWell and the financial performance of the combined group.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Humana | Brand | Medicare Advantage Part D Medicaid dental vision and other health coverage |
| CenterWell | Brand | Healthcare services identity spanning primary care pharmacy and home health |
| CenterWell Senior Primary Care | Brand | Senior-focused medical practices including jointly financed clinic operations |
| Conviva Senior Primary Care | Brand | Senior-focused primary care clinics and physician networks |
| CenterWell Home Health | Brand | Home health business incorporating former Kindred at Home operations |
| CenterWell Pharmacy | Brand | Home delivery pharmacy and medication services |
| CenterWell Specialty Pharmacy | Brand | Specialty medication dispensing and support |
| CarePlus Health Plans | Subsidiary | Florida Medicare Advantage health plans |
| Humana Military | Subsidiary | Military healthcare administration and TRICARE services |
| onehome | Subsidiary | Coordinated home healthcare delivery and benefit management |
| Independent Care Health Plan | Subsidiary | Wisconsin health plan known as iCare |
| Inclusa | Subsidiary | Wisconsin Medicaid long-term care organization acquired in 2023 |
| The Villages Health | Subsidiary | Florida primary and specialty care practice acquired by CenterWell in 2025 |
| Go365 | Brand | Health engagement rewards and wellness program |
Portfolio Analysis
Humana and CenterWell address different parts of the healthcare relationship. Insurance products collect premiums and assume covered medical risk, while CenterWell provides primary care, pharmacy and home health services. Conviva, CarePlus and Humana Military preserve identities suited to specific patient populations and programs. onehome adds coordination across home-based services.The portfolio's logic is to intervene earlier in care and reduce avoidable medical spending, while earning service revenue from multiple insurers. We find the distinction between wholly owned businesses and financed clinic partnerships important. CenterWell's year-to-date 2026 primary care patient growth of 30% creates scale, but new clinics require capital and time to mature. Integrating the Kindred home health platform and adding The Villages Health broaden delivery capabilities without guaranteeing that all insurance claims costs will decline.The separation of insurance and service identities also allows Humana to serve patients who are not enrolled in a Humana plan. That broadens the potential customer base for CenterWell and Conviva, while requiring the practices to remain attractive to multiple payers. That independence is commercially useful because clinic utilization need not depend entirely on the parent's insurance membership. It also means that a patient relationship at a CenterWell facility does not prove that Humana bears the insurance risk for the patient's wider care or receives every associated premium dollar.Home health, pharmacy and senior primary care each address a different part of the care journey. Their strategic fit depends on clinical coordination, patient access and the cost of delivering services, rather than a shared name alone. The combination can improve information and continuity, but the businesses still require skilled labor, useful locations and efficient operations. CarePlus, iCare and Inclusa add insurance and program-specific capabilities within particular markets. The strongest portfolio outcome would be a collection of well-run services that supports better patient economics while earning acceptable returns independently of promotional claims about integration.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Humana ★ | 20% | $129.664B | March 2026 United States Medicare Advantage enrollment share and FY2025 group revenue |
| UnitedHealth Group | 26% | $447.567B | March 2026 United States Medicare Advantage enrollment share and FY2025 group revenue |
| CVS Health | 12% | N/A | March 2026 United States Medicare Advantage enrollment share through Aetna |
| Kaiser Permanente | 6% | N/A | March 2026 United States Medicare Advantage enrollment share and integrated delivery model |
| Elevance Health | 5% | N/A | March 2026 United States Medicare Advantage enrollment share |
Competitive Analysis
Humana held approximately 20% of United States Medicare Advantage enrollment in March 2026, behind UnitedHealth's 26% and ahead of CVS Health's 12%. Those are enrollment shares within a defined program, while Humana's $129.664 billion revenue includes a broader set of activities. Competitive conditions also vary sharply by county and provider network.We regard enrollment growth as valuable only when premiums adequately cover expected medical utilization. The third-quarter 2026 benefit ratio of 93.7% demonstrates why pricing, care management and contract quality matter alongside scale. CenterWell can improve coordination and retain a portion of service economics, but clinical operations introduce their own labor and expansion costs. Quality ratings and reimbursement rules can change the relative attractiveness of plans even when an insurer retains strong national brand recognition.National enrollment shares can conceal very different local positions. A plan's attractiveness depends on the physicians and hospitals available to members, premiums and benefits, service quality and the insurer's expected medical cost. A strong position in one county does not automatically create an equally competitive offering elsewhere. The 20% national share consequently does not establish a uniform advantage across every market. It provides scale, but the economic value of that scale depends on a network and product design that can be priced adequately for the people actually enrolled.CenterWell creates another dimension of competition because Humana also participates in care delivery and pharmacy services. Those businesses can capture additional economics while introducing operating costs that a health plan alone would not incur. The combination is most attractive when coordination improves outcomes and reduces avoidable utilization without discouraging other payers from using the services. The challenge is simultaneous execution: the insurance book needs adequate pricing, and the clinical businesses need efficient delivery and appropriate growth. Strong membership numbers or a larger clinic network cannot independently demonstrate that the combined system earns an adequate return.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| CarePlus Health Plans | $408M | 2005 | Florida Medicare Advantage expansion |
| Metropolitan Health Networks | $850M | 2012 | Approximately announced transaction value plus costs for physician network and primary care platform |
| Independent Care Health Plan | undisclosed | 2020 | Acquired remaining interest in Wisconsin health plan |
| Kindred at Home remaining 60 percent | $5.7B | 2021 | Purchase of remaining interest rather than valuation of the entire home health and hospice company |
| onehome | undisclosed | 2021 | Home-based care management and delivery business |
| Inclusa | undisclosed | 2023 | Wisconsin Medicaid long-term care organization |
| The Villages Health | undisclosed | 2025 | Florida care delivery business acquired through CenterWell |
Acquisitions Analysis
Humana's acquisition history increasingly connects health coverage with direct care. CarePlus expanded Florida Medicare Advantage for $408 million in 2005, while Metropolitan Health Networks added physician and primary care capabilities in an approximately $850 million transaction in 2012. The 2021 Kindred at Home buyout required about $5.7 billion for the remaining 60% interest.onehome, iCare, Inclusa and The Villages Health extended home-based care, Medicaid and medical practice operations. They address different parts of the challenge of coordinating care for patients with complex needs while controlling total cost. Acquisition prices must nevertheless be matched to the specific interest purchased. The Kindred payment was not a valuation of the entire company. Subsequent hospice disposals also show that Humana has selectively retained assets closest to its preferred care model.The Kindred sequence is particularly informative because the purchase was followed by a decision to retain some capabilities and sell others. Home health remained close to the preferred operating model, while hospice and personal care interests were reduced. The net capital committed and the retained cash-generating assets need to be assessed together, rather than treating the buyout and later disposals as unrelated successes. A large acquisition can be strategically useful even when it is followed by selective sales, but the resulting portfolio still has to justify the financial resources consumed across the full sequence.Smaller health-plan and medical-practice purchases involve different integration requirements. A Medicaid organization brings program, network and local operating responsibilities, while a primary care practice brings clinical staff and patient relationships. Neither can be integrated solely by changing its brand. The value of The Villages Health, Inclusa or onehome depends on maintaining those operating capabilities while connecting them appropriately to the wider group. Acquisitions should therefore be judged through the quality and economics of the services delivered after closing, including the investment needed to preserve capacity, rather than only through the added number of patients or locations.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Humana's 1993 hospital spin-off established a lasting separation between its former hospital business and the health insurer. Proposed combinations with UnitedHealthcare in 1998 and Aetna in 2015 did not create a new controlling parent. The Aetna agreement, valued at approximately $37 billion, was terminated in 2017 following an antitrust ruling.More recent transactions have reshaped care delivery rather than the parent company's ownership. Humana sold 60% of the Kindred hospice and personal care business in 2022, then announced a roughly $900 million sale agreement for its remaining Gentiva interest in 2026. Those steps narrowed the retained portfolio toward home health and senior care. The clinic partnership announced with BlackRock similarly changes asset financing while preserving CenterWell's operating role and Humana's independent public-company identity.The blocked Aetna transaction is important because it prevents a common ownership misconception from becoming embedded in the company's history. A proposed sale is not the same as a completed acquisition, and its announced value did not become the value of an outside parent's continuing ownership stake. Humana remained an independently governed insurer. The subsequent expansion of care services followed that continuing independence: the company continued to pursue a business model within its own listed structure rather than becoming an operating division inside Aetna or the later CVS group.The Galen separation addressed a different question about the relationship between hospitals and insurance. Removing the hospital business changed the exposure held by Humana shareholders, while leaving the health-plan operation to develop separately. Current clinic investment does not simply recreate that former hospital portfolio. CenterWell emphasizes different settings and ownership arrangements, including outside financing for selected clinics. Comparing the two periods helps clarify that integration can take multiple forms. The economic issue is not whether Humana owns more healthcare assets in general, but whether the particular assets retained and financed support the services and returns the group now seeks to deliver.
Ownership History
Ownership History Analysis
David Jones and Wendell Cherry founded the business in 1961, and Extendicare became publicly traded in 1968 before adopting the Humana name in 1974. Its movement from nursing homes into hospitals and then insurance changed what shareholders owned much more dramatically than the continuity of the brand suggests.The 1993 hospital separation and the failed Aetna transaction in 2017 were decisive points in that evolution. Contemporary ownership rests principally with institutional portfolios, including Dodge & Cox at approximately 9.11% and BlackRock at 8.68% in the June 2026 positions. CenterWell's expansion changes operating scope within that continuing public ownership structure. Partnerships can bring outside capital into particular clinics, but they should not be mistaken for restoration of founder control or acquisition of the parent by an insurer.The continuity of the Humana name can make the underlying transformation appear less extensive than it was. Nursing homes, hospitals, health plans and the newer service platform represent different ways of participating in healthcare. Public investors retained a claim on the listed company as its operating emphasis changed, but the balance of risks behind that claim did not remain fixed. Those historical milestones reveal changes in capital allocation and business scope, rather than a direct continuation of the founders' initial operating structure.The institutional register now provides the main mechanism for outside financial oversight, while regulation and healthcare contracts impose additional practical constraints. CenterWell's growth has brought new partners into individual assets without changing that broad parent-level ownership. A shareholder in HUM therefore owns a changing combination of insurance economics, service operations and partial interests, not a direct share in every provider serving a member. That distinction connects the company's early separations with its current partnerships. Ownership history matters because it explains which capabilities stayed inside the group, which were distributed or sold, and where future capital commitments now sit.
Ownership Explained
Humana is an independent public healthcare company owned by shareholders of its NYSE-listed HUM common stock. It is not owned by Aetna, CVS Health or UnitedHealth Group. A proposed Aetna acquisition was terminated in 2017 after a federal antitrust ruling. The largest June 2026 institutional positions included Dodge & Cox at approximately 9.11%, BlackRock at 8.68% and Vanguard Capital Management at 6.53%.Founded in 1961 as a nursing home business, Humana later became a hospital operator and health insurer. Its 1993 hospital separation shifted the company toward health plans. Today its two principal identities are Humana for insurance and CenterWell for healthcare services, including senior primary care, pharmacy and home health. The company reported $129.664 billion of 2025 revenue and approximately 67,060 employees.Third-quarter 2026 revenue was $41.155 billion, and the insurance benefit ratio was 93.7%. Humana raised its full-year adjusted earnings outlook to at least $9.50 per share in November. Its October clinic joint-venture announcement involved BlackRock-managed capital and continued CenterWell operations; it did not give BlackRock majority ownership of Humana. Humana also announced a 2026 agreement to sell all or substantially all of its Gentiva minority interest for approximately $900 million. These transactions reflect changes within the care-delivery portfolio rather than a sale of the listed parent.Humana's economic exposure is concentrated in government-sponsored healthcare, where enrollment growth must be balanced against medical costs and reimbursement conditions. CenterWell adds the ability to deliver care and pharmacy services rather than only reimburse external providers, but those operations have their own staffing, expansion and financing requirements. The insurance and care-delivery activities can reinforce one another without being interchangeable. Ownership of the parent gives shareholders exposure to their combined results, while patient coverage, clinic operation and investment partnership rights remain defined at the relevant business level. That distinction is particularly important when interpreting the growth of CenterWell alongside pressure on insurance margins.
Humana shareholders have voting rights in the parent, while health insurance subsidiaries remain subject to their own capital and regulatory requirements. Premium revenue is not cash freely available for distribution because claims, reserves and statutory capital must be funded first.Patients may encounter CenterWell or Conviva while covered by a different insurer. Those care brands serve multiple payers, and some clinic assets use joint-venture financing. BlackRock's role as a clinic investment partner is separate from the minority HUM shares held in its investment portfolios. For employees and investors, that distinction determines who supplies capital, who operates the clinics and where the economic returns are shared.